Pharsight

Aveed is owned by Endo Pharms Inc.

Aveed contains Testosterone Undecanoate.

Aveed has a total of 2 drug patents out of which 0 drug patents have expired.

Aveed was authorised for market use on 05 March, 2014.

Aveed is available in injectable;intramuscular dosage forms.

Aveed can be used as testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired); hypogonadotropic hypogonadism (congenital or acquired)..

The generics of Aveed are possible to be released after 08 May, 2027.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640	ENDO PHARMS INC	Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels	Mar, 2027 (3 years from now)
US8338395	ENDO PHARMS INC	Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels	May, 2027 (3 years from now)

Do you want to check out AVEED patents from before 2022?

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 05 March, 2014

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: INJECTABLE;INTRAMUSCULAR